Laura is the vice president of content for The American Journal of Managed Care® (AJMC®) and all its brands, including Population Health, Equity & Outcomes; Evidence-Based Oncology™; and The Center for Biosimilars®. She has been working on AJMC since 2014 and has been with AJMC’s parent company, MJH Life Sciences®, since 2011.
She has an MA in business and economic reporting from New York University. You can connect with Laura on LinkedIn or Twitter.
Revumenib’s Safety Profile and Path to Formulary: Ivo Abraham, PhD, RN
July 20th 2025Revumenib is now the sole targeted therapy recommended by the National Comprehensive Cancer Network for KMT2A-rearranged acute leukemia, which opens a path for payers, said Ivo Abraham, PhD, RN, of The University of Arizona.
New Blueprint Guides Patient-Centered Research for More Equitable Health Care
July 17th 2025The new Blueprint for Patient-Centered Value Research offers a roadmap for embedding patient voices throughout every stage of the research journey to foster more equitable, transparent, and responsive health care systems.
The Future of Drug Pricing: Most Favored Nation, PBMs, and Patient Access
July 11th 2025During the Reshaping Rx: Navigating 2025 Drug Pricing Policies webinar, panelists discussed the Most Favored Nation executive order, bills aimed at pharmacy benefit managers (PBMs), and other drug pricing policies.
What Will AI in Health Care Look Like in the Future?
July 10th 2025Artificial intelligence (AI) transforms oncology by enhancing clinical decision-making, improving patient outcomes, and shaping future health care training, as discussed by experts at Tennessee Oncology's “Tech Innovations in Community Oncology."
Using AI for the Medical Note: Game Changer or a Bridge Too Far?
July 9th 2025During the “Tech Innovations in Community Oncology” meeting from Tennessee Oncology, oncologists explore artificial intelligence (AI) tools like DeepScribe to enhance documentation efficiency, reduce burnout, and improve patient engagement in clinical settings.
Practical Considerations for AI in Community Oncology
July 8th 2025Artificial intelligence (AI) transforms oncology by enhancing decision-making, improving patient care, and streamlining operations, while addressing challenges in data accuracy and equity, said speakers at the Tennessee Oncology “Tech Innovations in Community Oncology."
How AI Can Address the Troubled Business Model in Oncology
July 7th 2025Artificial intelligence (AI) will transform community oncology, addressing workforce shortages and reimbursement challenges while enhancing patient care and operational efficiency, discussed speakers at Tennessee Oncology's “Tech Innovations in Community Oncology."